TrialBritish journal of cancer2025

Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy.

Sanjay Popat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.